COLL
Price
$33.94
Change
+$0.73 (+2.20%)
Updated
Oct 17 closing price
Capitalization
1.07B
19 days until earnings call
ZTS
Price
$144.06
Change
+$0.80 (+0.56%)
Updated
Oct 17 closing price
Capitalization
63.85B
17 days until earnings call
Interact to see
Advertisement

COLL vs ZTS

Header iconCOLL vs ZTS Comparison
Open Charts COLL vs ZTSBanner chart's image
Collegium Pharmaceutical
Price$33.94
Change+$0.73 (+2.20%)
Volume$426.96K
Capitalization1.07B
ZOETIS
Price$144.06
Change+$0.80 (+0.56%)
Volume$3.75M
Capitalization63.85B
COLL vs ZTS Comparison Chart in %
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
COLL vs. ZTS commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a Hold and ZTS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (COLL: $33.94 vs. ZTS: $144.06)
Brand notoriety: COLL: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: COLL: 106% vs. ZTS: 138%
Market capitalization -- COLL: $1.07B vs. ZTS: $63.85B
COLL [@Pharmaceuticals: Generic] is valued at $1.07B. ZTS’s [@Pharmaceuticals: Generic] market capitalization is $63.85B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.85B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.96B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COLL’s FA Score shows that 1 FA rating(s) are green whileZTS’s FA Score has 1 green FA rating(s).

  • COLL’s FA Score: 1 green, 4 red.
  • ZTS’s FA Score: 1 green, 4 red.
According to our system of comparison, COLL is a better buy in the long-term than ZTS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COLL’s TA Score shows that 5 TA indicator(s) are bullish while ZTS’s TA Score has 5 bullish TA indicator(s).

  • COLL’s TA Score: 5 bullish, 5 bearish.
  • ZTS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ZTS is a better buy in the short-term than COLL.

Price Growth

COLL (@Pharmaceuticals: Generic) experienced а +5.93% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was +2.09% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.79%. For the same industry, the average monthly price growth was +4.23%, and the average quarterly price growth was +51.45%.

Reported Earning Dates

COLL is expected to report earnings on Nov 06, 2025.

ZTS is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.79% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($63.8B) has a higher market cap than COLL($1.07B). COLL has higher P/E ratio than ZTS: COLL (32.02) vs ZTS (24.80). COLL YTD gains are higher at: 18.464 vs. ZTS (-10.718). ZTS has higher annual earnings (EBITDA): 4.02B vs. COLL (347M). ZTS has more cash in the bank: 1.44B vs. COLL (222M). COLL has less debt than ZTS: COLL (829M) vs ZTS (6.79B). ZTS has higher revenues than COLL: ZTS (9.39B) vs COLL (707M).
COLLZTSCOLL / ZTS
Capitalization1.07B63.8B2%
EBITDA347M4.02B9%
Gain YTD18.464-10.718-172%
P/E Ratio32.0224.80129%
Revenue707M9.39B8%
Total Cash222M1.44B15%
Total Debt829M6.79B12%
FUNDAMENTALS RATINGS
COLL vs ZTS: Fundamental Ratings
COLL
ZTS
OUTLOOK RATING
1..100
962
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
34
Fair valued
PROFIT vs RISK RATING
1..100
50100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9339
P/E GROWTH RATING
1..100
684
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZTS's Valuation (34) in the Pharmaceuticals Generic industry is in the same range as COLL (65) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew similarly to COLL’s over the last 12 months.

COLL's Profit vs Risk Rating (50) in the Pharmaceuticals Other industry is somewhat better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that COLL’s stock grew somewhat faster than ZTS’s over the last 12 months.

COLL's SMR Rating (100) in the Pharmaceuticals Other industry is in the same range as ZTS (100) in the Pharmaceuticals Generic industry. This means that COLL’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's Price Growth Rating (39) in the Pharmaceuticals Generic industry is somewhat better than the same rating for COLL (93) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew somewhat faster than COLL’s over the last 12 months.

COLL's P/E Growth Rating (6) in the Pharmaceuticals Other industry is significantly better than the same rating for ZTS (84) in the Pharmaceuticals Generic industry. This means that COLL’s stock grew significantly faster than ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COLLZTS
RSI
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
67%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
49%
Momentum
ODDS (%)
N/A
Bearish Trend 3 days ago
66%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
57%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 3 days ago
59%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
60%
Advances
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 5 days ago
56%
Declines
ODDS (%)
Bearish Trend 11 days ago
65%
Bearish Trend 9 days ago
58%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
70%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 3 days ago
60%
View a ticker or compare two or three
Interact to see
Advertisement
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IARCX16.870.11
+0.66%
Invesco Real Estate C
JMVCX15.700.10
+0.64%
Janus Henderson Mid Cap Value C
ILGGX24.510.13
+0.53%
Columbia Integrated Large Cap Gr Instl
MFRCX52.730.26
+0.50%
MFS Research C
RYGRX93.680.07
+0.07%
Rydex S&P 500 Pure Growth C

COLL and

Correlation & Price change

A.I.dvisor indicates that over the last year, COLL has been loosely correlated with AMPH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then AMPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
+2.20%
AMPH - COLL
41%
Loosely correlated
+2.41%
AMRX - COLL
40%
Loosely correlated
+0.51%
VTRS - COLL
38%
Loosely correlated
+0.69%
PAHC - COLL
34%
Loosely correlated
+2.98%
ZTS - COLL
34%
Loosely correlated
+0.56%
More

ZTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
+0.56%
ELAN - ZTS
48%
Loosely correlated
+4.39%
VTRS - ZTS
48%
Loosely correlated
+0.69%
PAHC - ZTS
42%
Loosely correlated
+2.98%
HLN - ZTS
39%
Loosely correlated
+3.04%
AMRX - ZTS
38%
Loosely correlated
+0.51%
More